/**/ RNS Number : 6987T Imaging Biometrics Limited 19 February 2026   Imaging Biometrics Limited (“IBAI” or the “Company”)   Board Appointment   Imaging Biometrics Limited (LSE: IBAI) is pleased to announce the appointment of John Charles Richardson as a Non-Executive Director with effect from 1 March 2026 and will become a member of the

/**/ RNS Number : 4979S Imaging Biometrics Limited 11 February 2026   Imaging Biometrics Limited (“IBAI” or the “Company”) Company Update IB Nimble Webinar – 27 February 2026   Imaging Biometrics Limited (‘IBAI’) comprises two subsidiary businesses, Imaging Biometrics LLC and Kirkstall Limited. In 2018, Imaging Biometrics, LLC (‘IB’) was acquired by Flying Brands Limited

/**/ RNS Number : 1365P Imaging Biometrics Limited 16 January 2026   Imaging Biometrics, Ltd (“IBAI” or the “Company”)   IBAI Sets Strategic Direction Fueling Organic Growth   Imaging Biometrics, Ltd, (LSE: IBAI) is pleased to provide an update on its involvement in the development of gallium maltolate as well as its strategic priorities for

/**/ RNS Number : 0116L Imaging Biometrics Limited 10 December 2025   December 10, 2025 Imaging Biometrics, Ltd (“IBAI” or the “Company”)   Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetric™   Imaging Biometrics (IB), a leader in advanced neuroimaging solutions, announces an amendment to its distribution

/**/ RNS Number : 1481J Imaging Biometrics Limited 26 November 2025   Imaging Biometrics, Ltd (“IBAI” or the “Company”)   Imaging Biometrics Announces Release of Next-Generation IB Clinic   Imaging Biometrics, LLC, (“IB”), a leader in advanced quantitative imaging solutions, is pleased to announce the release of the next version of IB Clinic, its comprehensive

/**/ RNS Number : 7342I Imaging Biometrics Limited 24 November 2025   Imaging Biometrics Limited (“IBAI” or the “Company”)   Board Changes   The Company announces that Dr Al Musella will step down from the Board of Directors with effect from 31 December 2025.   Although Dr Musella will no longer serve on the IBAI

/**/ RNS Number : 4541H Imaging Biometrics Limited 13 November 2025   Imaging Biometrics Limited (“IB” or the “Company”)   Imaging Biometrics’ Fractional Tumor Burden Mapping Enhances GBM Trial   A glioblastoma (GBM) clinical trial led by Dr. Danielle Bazer, DO, neuro-oncologist and Lead for Neuro-Oncology at MD Anderson Cancer Center at Cooper University, is

/**/ RNS Number : 9232G Imaging Biometrics Limited 10 November 2025   Imaging Biometrics, Ltd (the “Company”)   Imaging Biometrics Announces Successful Completion of Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma   Imaging Biometrics, LLC, (“IB”), a leader in advanced quantitative imaging solutions, today announces the successful completion of its Phase 1 clinical

/**/ RNS Number : 5711D Imaging Biometrics Limited 16 October 2025   Imaging Biometrics Limited (“IBAI” or the “Company”) Further Re: Purchase of interest in Kirkstall Limited Imaging Biometrics Limited Limited (LSE: IBAI), provides an update following its announcement on 14 October 2025 regarding the purchase of the Company‘s interest in Kirkstall Limited (“Kirkstall”) from Truetide

/**/ RNS Number : 3286D Imaging Biometrics Limited 14 October 2025   Imaging Biometrics Limited (“IBAI” or the “Company”)   Purchase of Kirkstall Limited and CLN with Truetide plc – Correction   The following amendment has been made to the Purchase of Kirkstall Limited and CLN with Trueside plc announcement released on 14.10.25 at 7am.